SEC Form 4 · accession 0001104659-16-144630
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon Congleton
Officer — President and CEO · Director
Period of report
Sep 12, 2016
Accepted (ET)
Sep 14, 2016 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $7.77 | Sep 12, 2016 | A | 250,000 | A | — | Sep 12, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- F2The options vest and become exercisable over a four-year period, with 25% vesting on the first anniversary of the grant date (September 12, 2017) and 1/48th of the options vesting monthly thereafter.